Abbonarsi

Inter-α-trypsin inhibitor heavy chain 4 (ITIH4) as a compensatory protease inhibitor in hereditary angioedema - 05/08/24

Doi : 10.1016/j.jaci.2024.03.028 
Anne Troldborg, MD, PhD a, b, c, , Zsofia Godnic-Polai, PhD d, László Cervenak, PhD e, Annette G. Hansen, BA a, Henriette Farkas, MD, PhD, DSc d, Steffen Thiel, PhD a
a Department of Biomedicine, Aarhus University, Aarhus, Denmark 
b Department of Clinical Medicine, Aarhus University, Aarhus, Denmark 
c Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark 
d Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary 
e Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary 

Corresponding author: Anne Troldborg, MD, PhD, Department of Biomedicine, Aarhus University, Aarhus, Denmark.Department of BiomedicineAarhus UniversityAarhusDenmark

Abstract

Background

Hereditary angioedema (HAE) is a genetic disorder that manifests as recurrent angioedema attacks, most frequently due to absent or reduced C1 inhibitor (C1INH) activity. C1INH is a crucial regulator of enzymatic cascades in the complement, fibrinolytic, and contact systems. Inter-α-trypsin inhibitor heavy chain 4 (ITIH4) is an abundant plasma protease inhibitor that can inhibit enzymes in the proteolytic pathways associated with HAE. Nothing is known about its role in HAE.

Objective

We investigated ITIH4 activation in HAE, establishing it as a potential biomarker, and explored its involvement in HAE-associated proteolytic pathways.

Methods

Specific immunoassays for noncleaved ITIH4 (intact ITIH4) and an assay detecting both intact and cleaved ITIH4 (total ITIH4) were developed. We initially tested serum samples from HAE patients (n = 20), angiotensin-converting enzyme inhibitor–induced edema patients (ACEI) (n = 20), and patients with HAE of unknown cause (HAE-UNK) (n = 20). Validation involved an extended cohort of 80 HAE patients (60 with HAE-C1INH type 1, 20 with HAE-C1INH type 2), including samples taken during attack and quiescent disease periods, as well as samples from 100 healthy controls.

Results

In 63% of HAE patients, intact ITIH4 assay showed lower signals than total ITIH4 assay. This difference was not observed in ACEI and HAE-UNK patients. Western blot analysis confirmed cleaved ITIH4 with low intact ITIH4 samples. In serum samples lacking intact endogenous ITIH4, we observed immediate cleavage of added recombinant ITIH4, suggesting continuous enzymatic activity in the serum. Confirmatory HAE cohort analysis revealed significantly lower intact ITIH4 levels in both type 1 and type 2 HAE patients compared to controls, with consistently low intact/total ITIH4 ratios during clinical HAE attacks.

Conclusion

The disease-specific low intact ITIH4 levels highlight its unique nature in HAE. ITIH4 may exhibit compensatory mechanisms in HAE, suggesting its utility as a diagnostic and prognostic biomarker. The variations during quiescent and active disease periods raise intriguing questions about the dynamics of proteolytic pathways in HAE.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Protease inhibitor activity, C1 inhibitor, hereditary angioedema, inter-α-trypsin inhibitor heavy chain 4, plasma kallikrein, enzymatic cascade

Abbreviations used : AAE-ACEI, ACE, ACEI, C1INH, EDTA, HAE, HAE-C1INH, HAE-UNK, HSA, ITIH4, KKS, rITIH4, RT, SERPING1, TBS, TBST


Mappa


 The first 2 authors contributed equally to this article, and both should be considered first author. The last 2 authors contributed equally to this article, and both should be considered senior author.


© 2024  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 154 - N° 2

P. 468 - Agosto 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease
  • Chongjia C. Chen, Kathleen M. Buchheit, Pui Y. Lee, Kailey E. Brodeur, Aaqib Sohail, Laura Cho, Carolyn H. Baloh, Barbara Balestrieri, Tahereh Derakhshan, Chunli Feng, Joshua A. Boyce, Daniel F. Dwyer, Tanya M. Laidlaw
| Articolo seguente Articolo seguente
  • Thymic stromal lymphopoietin induces IL-4/IL-13 from T cells to promote sebum secretion and adipose loss
  • Ruth Choa, Jordan C. Harris, EnJun Yang, Yuichi Yokoyama, Mariko Okumura, MinJu Kim, Jerrick To, Meng Lou, Amanda Nelson, Taku Kambayashi

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.